Pancragen is a synthetic Khavinson tetrapeptide (Lys‑Glu‑Asp‑Trp), also known as KEDW or the Khavinson pancreas peptide, marketed currently for pancreatic and metabolic support, although no specific community use cases have been reported. Community users generally most often take 2 mg per day with no consistent timing or cycling, while clinician sources describe a regimen of 20 mg per day administered subcutaneously. The overall sole tradeoff noted in the evidence is that Pancragen lacks FDA‑approved indication, meaning all human use is off‑label or compounded.
Data last updated
Measured on 2 of 6 axes
Evidence shape
Pancragen is classified as animal‑only evidence, with zero published human studies and no registered clinical trials. The breadth of the literature maps to a single animal‑only indication—preclinical/mechanistic research—and there are no populated or thin human indications. Quality reflects the absence of any completed trials, meaning there is no human data of any kind, and no data indications are recorded at present, and the evidence base currently remains exclusively preclinical.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column · 4 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How Pancragen is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
The clinician practice tier lists a 20 mg subcutaneous dose of Pancragen, with no stated frequency or cycling regimen, according to the source.
The sole community report indicates a dose of 2 mg administered subcutaneously once per week, with no mention of cycling or alternative frequencies.